LSP launches US-$600m European life sciences fund
LSP has closed its LSP 6 fund at the $600m hard cap. It is the largest fund ever raised in Europe focused on life sciences ventures.
Biotalys grabs 45m in Series C financing
Pest control specialist Biotalys NV has raised an additional 10m to its series C financing bringing its amount to 45m.
German and UK researchers cut time to sepsis diagnosis
Researchers from German Fraunhofer IGBI have used next-generation sequencing (NGS) to diagnosis sepsis from tiny amounts of microbial DNA in the blood.
IMI launches 45m call for coronavirus emergency
The Innovative Medicines Initiative (IMI) has announced a 45m funding for the development of therapeutics and diagnostics to tackle coronavirus outbreaks.
Immunocore Ltd raises US$130m in Series B round
With the financing led by General Atlantic, the British company wants to expand a novel platform and advance its ImmTAX pipeline to the clinic.
Vitamin C may boost checkpoint inhibitor efficacy
High amounts of injected vitamin C may delay the growth of many types of tumours and boost the anticancer power of immune checkpoint therapies, report Italian oncologists.
Roche grabs Bicycle Therapeutics platform
Roche AGs has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plcs technology platform to target immune checkpoints.
Microglia inhibitor stops neuronal cell death after TBI
Post-Brexit budget drives cuts in Horizon Europe
Negotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM acquires Glycom A/S for 765m
Royal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2-fucosyl lactose, Danish Glycom A/S.